Columbia Biotechnologies Corporation, a privately-held C corp., is engaged in both Biotherapeutic and Chemotherapeutic research and development. Columbia Biotechnologies is now working in collaboration with the Oregon Health and Sciences University (OHSU) to develop biomedical technologies of mutual interest. The company currently focuses on the research and development of novel therapeutics to treat inflammatory- proliferative skin diseases (e.g. Psoriasis) and Alcohol Withdrawal Syndrome (AWS).
